Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 2/20 | 0.61 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | CLK3 | P49761 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | OXTR | P30559 | 1/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20069366 | 0.92 | TDO2 (0.54) | TDO2HRH3TLR7OXTRAVPR1A | |
| SCHEMBL19865665 | 0.92 | TDO2 (0.54) | TDO2HRH3TLR7OXTRAVPR1A | |
| SCHEMBL19865633 | 0.92 | TDO2 (0.54) | TDO2HRH3TLR7OXTRAVPR1A | |
| SCHEMBL20145024 | 0.85 | TDO2 (0.48) | TDO2HRH3TLR7 | |
| SCHEMBL20147458 | 0.85 | HRH3 (0.56) | TDO2HRH3NAMPTLIPE | |
| SCHEMBL31277351 | 0.85 | TDO2 (0.47) | TDO2HRH3LIPEOXTRAVPR1A | |
| SCHEMBL16382664 | 0.84 | TDO2 (0.45) | TDO2TLR7OXTRAVPR1A | |
| SCHEMBL22856982 | 0.84 | TDO2 (0.46) | TDO2HRH3LIPEOXTRAVPR1A | |
| SCHEMBL13432215 | 0.83 | TDO2 (0.50) | TDO2HRH3NAMPTTLR7PIK3CA | |
| SCHEMBL20152055 | 0.82 | HRH3 (0.48) | TDO2HRH3NAMPTLIPEOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | TDO2 4376/4885MAPK7 253/4885HRH3 1000/4885 |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | TDO2 4376/4885MAPK7 253/4885HRH3 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.